Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 11/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 11/20 | 0.40 |
| ▸ | HTR5A | P47898 | 5/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907523 | 0.68 | HTR5A (0.69) | CSNK2A2CSNK2BHTR5A | |
| SCHEMBL2680048 | 0.68 | TTR (0.43) | CSNK2A2CSNK2BHTR5A | |
| SCHEMBL9907629 | 0.68 | HTR5A (0.71) | CSNK2A2CSNK2BHTR5AMAPK14 | |
| SCHEMBL9907741 | 0.67 | HTR5A (0.58) | HTR5A | |
| SCHEMBL12743670 | 0.67 | CSNK2A2 (0.66) | CSNK2A2CSNK2B | |
| SCHEMBL9907597 | 0.66 | TTR (0.45) | CSNK2A2CSNK2BHTR5A | |
| SCHEMBL9907684 | 0.66 | HTR5A (0.53) | CSNK2A2CSNK2BHTR5A | |
| SCHEMBL9907642 | 0.66 | HTR5A (0.57) | CSNK2A2CSNK2BHTR5A | |
| SCHEMBL9909272 | 0.66 | HTR5A (0.74) | HTR5A | |
| SCHEMBL9907658 | 0.65 | HTR5A (0.71) | CSNK2A2CSNK2BHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461175-B2 | 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, CYP4F3, HCCS | CSNK2A2 1606/4885CSNK2B 1346/4885HTR5A 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.